Clinical Trials Browser

Androgen Receptor Antagonists × Clear all

NCT04946370 2026-02-03

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 1/2 Terminated

Bites and Stings

NCT03899467 2024-02-12

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Phase 2 Completed

61 enrolled 12 charts

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT02987829 2021-04-23

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Phase 1/2 Completed

72 enrolled 19 charts

Adenocarcinoma

NCT02826772 2020-03-17

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Phase 1 Completed

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT00103376 2018-11-05

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Phase 2 Terminated

23 enrolled 9 charts

Prostatic Neoplasms